Bill Maris

However, because of the

However, because of the

human biology and the FDA, if you find a compound and you think you've got something, that's like 5% of the work.

human biology and the FDA, if you find a compound and you think you've got something, that's like 5% of the work.

There's still all kinds of titrating and safety testing that needs to go on.

There's still all kinds of titrating and safety testing that needs to go on.

And so I don't think it's gonna go quite as exponential as we would all like it to.

And so I don't think it's gonna go quite as exponential as we would all like it to.

However, if we can achieve a realistic stimulation of a human cell in silico, then you will see that accelerate as well.

However, if we can achieve a realistic stimulation of a human cell in silico, then you will see that accelerate as well.

We're not quite there yet.

We're not quite there yet.

I think the US has always indexed on human safety over speed to market, and that has cost us in some ways.

I think the US has always indexed on human safety over speed to market, and that has cost us in some ways.

However...

However...

Some other countries are indexed in the opposite direction, which costs lives.

Some other countries are indexed in the opposite direction, which costs lives.

So there's a balance there.

So there's a balance there.